JP2025501610A5 - - Google Patents
Info
- Publication number
- JP2025501610A5 JP2025501610A5 JP2024538261A JP2024538261A JP2025501610A5 JP 2025501610 A5 JP2025501610 A5 JP 2025501610A5 JP 2024538261 A JP2024538261 A JP 2024538261A JP 2024538261 A JP2024538261 A JP 2024538261A JP 2025501610 A5 JP2025501610 A5 JP 2025501610A5
- Authority
- JP
- Japan
- Prior art keywords
- saponin
- receptor
- composition
- ligand
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2030216 | 2021-12-22 | ||
| NL2030216 | 2021-12-22 | ||
| PCT/NL2022/050734 WO2023121444A1 (en) | 2021-12-22 | 2022-12-20 | Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501610A JP2025501610A (ja) | 2025-01-22 |
| JP2025501610A5 true JP2025501610A5 (https=) | 2025-11-26 |
Family
ID=81585853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538261A Pending JP2025501610A (ja) | 2021-12-22 | 2022-12-20 | 筋消耗性障害の治療のための治療用核酸と標的型サポニンとを含む組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250082759A1 (https=) |
| EP (1) | EP4452324A1 (https=) |
| JP (1) | JP2025501610A (https=) |
| KR (1) | KR20240125934A (https=) |
| CN (1) | CN118434449A (https=) |
| CA (1) | CA3240611A1 (https=) |
| IL (1) | IL313731A (https=) |
| WO (1) | WO2023121444A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20260025101A (ko) * | 2023-06-02 | 2026-02-23 | 사프렘 테크놀로지스 비.브이. | 세포내 분자 표적을 통해 작용하는 치료적 이펙터 성분을 위한 개선된 치료 요법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US10626395B2 (en) | 2016-10-27 | 2020-04-21 | The General Hospital Corporation | Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| IL280536B2 (en) | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| SG11202106603UA (en) | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Biologically active cluster of molecules |
| CA3163283A1 (en) | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
-
2022
- 2022-12-20 WO PCT/NL2022/050734 patent/WO2023121444A1/en not_active Ceased
- 2022-12-20 KR KR1020247021548A patent/KR20240125934A/ko active Pending
- 2022-12-20 EP EP22830323.6A patent/EP4452324A1/en active Pending
- 2022-12-20 CA CA3240611A patent/CA3240611A1/en active Pending
- 2022-12-20 IL IL313731A patent/IL313731A/en unknown
- 2022-12-20 CN CN202280085040.3A patent/CN118434449A/zh active Pending
- 2022-12-20 JP JP2024538261A patent/JP2025501610A/ja active Pending
- 2022-12-20 US US18/723,096 patent/US20250082759A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501610A5 (https=) | ||
| JP2025500481A5 (https=) | ||
| JP2025500482A5 (https=) | ||
| CN106459969B (zh) | 用于调节生长激素受体表达的组合物和方法 | |
| ES3052234T3 (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| JP2022511866A (ja) | 化学修飾されたＲＮＡｉコンストラクト及びその使用 | |
| JP7197463B2 (ja) | Ｓｍｎ２の調節のための化合物及び方法 | |
| CN118434449A (zh) | 包含用于治疗肌肉消耗障碍的治疗性核酸和靶向皂苷的组合物 | |
| TW201505657A (zh) | 用於增強的細胞攝取之化合物及方法 | |
| US10538765B2 (en) | Organic compositions to treat EPAS1-related diseases | |
| JP2016523548A (ja) | 成長ホルモン受容体のモジュレータ | |
| JP2024505151A5 (https=) | ||
| AU2022258459A1 (en) | Compositions and methods for modulating pnpla3 expression | |
| JP2023542889A (ja) | 複数の標的を介して疼痛を処置するための治療用組成物 | |
| WO2023208109A1 (zh) | 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途 | |
| BR112021003609A2 (pt) | produtos e composições | |
| WO2023027759A1 (en) | Compositions and methods for inhibiting αlpha-1 antitrypsin expression | |
| JP2025528102A (ja) | アデニル酸シクラーゼ９（ａｃ９）を阻害するための組成物及び方法 | |
| JP2024519204A (ja) | 複数の標的を介して疼痛を処置するための治療組成物 | |
| EP4366785A1 (en) | Treatment for tyrosine degradation-associated disorders | |
| US20240150768A1 (en) | Methods for the treatment of nash with advanced fibrosis and/or cirrhosis | |
| US20240139230A1 (en) | Dosage regimen for the treatment of nash | |
| WO2025162482A1 (zh) | 用于预防和治疗癌症转移的aso及其用途 | |
| HK40129500A (en) | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |